After SEC Settlement, Eli Lilly 'Deeply Concerned' by Graft Allegations in Chinese Media

U.S. drugmaker Eli Lilly and Co said it was "deeply concerned" about allegations published in a Chinese newspaper that it spent more than 30 million yuan ($4.90 million) to bribe doctors in China to prescribe the firm's medicines instead of rival products.

Unlock unlimited access to all Global Investigations Review content